arglu1b Antibody

What is ARGLU1 and what are its primary molecular functions?

ARGLU1 (Arginine and Glutamate Rich 1) is a highly conserved protein with distinct functional domains: an arginine-rich N-terminus and a glutamate-rich C-terminus. Research has established ARGLU1 as both a transcriptional coactivator and RNA splicing modulator . The protein's C-terminal glutamate-rich domain functions as a coactivator for multiple nuclear receptors including the glucocorticoid receptor (GR), while the N-terminal arginine-rich region interacts with splicing factors and binds to RNA . ARGLU1 is particularly abundant in the central nervous system but is ubiquitously expressed across tissues .

Which experimental techniques are most effective for detecting ARGLU1 using antibodies?

ARGLU1 antibodies have been validated for multiple experimental applications:

These applications are supported by multiple antibody validation studies across human tissues .

What is the expression pattern of ARGLU1 across tissues, and how should this inform experimental design?

Tissue distribution analysis of ARGLU1 reveals highest expression in the central nervous system, with ubiquitous expression across other tissues. RT-qPCR measurements across 53 different mouse tissues demonstrated a strong correlation between ARGLU1 and glucocorticoid receptor (GR) expression patterns, with few exceptions (ARGLU1 is low in uterus and pancreas; GR is low in testis) .

When designing experiments:

• Neural tissue experiments should account for higher baseline expression

• Use appropriate positive controls based on tissue type

• Consider potential co-regulatory relationships with GR when studying endocrine signaling

• Western blot loading controls should be optimized for tissue-specific expression levels

What are the recommended positive and negative controls when validating ARGLU1 antibodies?

Recommended controls:

How can researchers effectively use ARGLU1 antibodies to investigate its dual role in transcriptional regulation and RNA splicing?

To investigate the transcriptional regulatory function:

• ChIP-seq experiments targeting ARGLU1 can identify genome-wide binding sites, focusing on promoter regions of nuclear receptor target genes

• Co-immunoprecipitation with antibodies against transcriptional machinery components (e.g., MED1) can validate protein-protein interactions

• Reporter gene assays with ARGLU1 antibody validation can confirm functional impact on transcription

For RNA splicing investigations:

• RNA immunoprecipitation (RIP) using ARGLU1 antibodies can identify bound RNA targets

• CLIP-seq (Cross-linking immunoprecipitation) experiments can map precise binding sites on target RNAs

• Alternative splicing analysis after ARGLU1 knockdown/overexpression, validated by ARGLU1 antibody-based Western blotting, can reveal functional impacts

Importantly, research has shown that ARGLU1 binding motifs include CGG(A/G)GG-rich sequences, similar to those bound by SRSF2, suggesting potential competitive or cooperative interactions in splicing regulation .

What methodological considerations are critical when using ARGLU1 antibodies for chromatin immunoprecipitation (ChIP)?

When performing ChIP with ARGLU1 antibodies:

• Crosslinking optimization: Use a standardized protocol (e.g., SimpleChIP protocol) with 1% formaldehyde for 10 minutes at room temperature

• Antibody selection: Use validated anti-ARGLU1 antibodies at appropriate concentrations (recommended: 10 μg/mL)

• Controls: Include IgG antibody controls (10 μg/mL) to assess non-specific binding

• Primer design: Design primers targeting genomic regions containing known binding motifs or near nuclear receptor response elements

• Quantification method: Quantify by genomic qPCR using serial dilutions of input as standard curve

• Data analysis: Express results as percent enrichment of bound DNA compared to each input sample

Research has demonstrated successful ChIP with ARGLU1 antibodies to identify recruitment to promoters of mismatch repair genes including MLH3, MSH2, MSH3, and MSH6 .

What role does ARGLU1 play in DNA damage response pathways, and how can antibodies be applied to investigate this function?

Recent research has revealed ARGLU1's involvement in DNA damage response pathways and cancer cell chemoresistance . ARGLU1 promotes DNA damage repair, possibly through enhancement of promoter-proximal pausing of RNA polymerase II .

To investigate this function using antibodies:

• Immunofluorescence co-localization: Use anti-ARGLU1 antibodies alongside DNA damage markers (γH2AX) to assess recruitment to DNA damage sites

• Chromatin fraction analysis: Employ subcellular fractionation followed by Western blotting with ARGLU1 antibodies to track protein recruitment after DNA damage

• ChIP-seq analysis: Use ARGLU1 antibodies to identify genomic binding sites after treatment with genotoxic drugs

• Sequential ChIP (re-ChIP): Apply to detect co-occupancy of ARGLU1 with DNA damage response factors

A methodological approach used in recent studies involved knockdown of ARGLU1, treatment with genotoxic drugs, and measurement of cell survival and DNA damage repair efficiency .

How can researchers accurately characterize protein-protein interactions involving ARGLU1 using antibody-based techniques?

ARGLU1 interacts with multiple protein partners including nuclear receptors, mediator complex proteins, and splicing factors . To characterize these interactions:

• Co-immunoprecipitation:

  • Crosslink antibodies to magnetic protein A/G beads

  • Block beads with 3% Block ACE solution (3 hours at room temperature)

  • Incubate beads with 1 mg total cell lysate (10 hours at 4°C)

  • Elute and analyze by Western blotting with antibodies against suspected interacting partners

• Immunoprecipitation followed by mass spectrometry (IP-MS):

  • Perform IP with anti-ARGLU1 antibodies

  • Elute with a mixture of 74% acetonitrile, 25.9% water, and 0.2% formic acid

  • Mix with sinapinic acid matrix

  • Analyze by mass spectrometry

• Proximity ligation assay (PLA):

  • Use anti-ARGLU1 antibodies with antibodies against potential interacting partners

  • Detect interaction by fluorescent signal when proteins are in close proximity (<40 nm)

Research has identified interactions between ARGLU1 and factors like MED1, JMJD6, BRD4, and various nuclear receptors .

What technical challenges exist in using ARGLU1 antibodies for detecting alternative splicing events, and how can they be overcome?

Detecting ARGLU1-mediated alternative splicing events presents several challenges:

Research has identified 426 alternative splicing events showing absolute dPSI of ≥15 in response to dexamethasone, with 92% of these events being ARGLU1-dependent, highlighting the importance of this protein in hormone-induced alternative splicing .

How can ARGLU1 antibodies be applied in cancer research, particularly for gastric cancer studies?

• Tissue microarray analysis:

  • Use anti-ARGLU1 antibodies (dilution 1:200) on tissue microarrays

  • Score staining intensity and proportion of cell staining

  • Correlate with clinical parameters and survival data

• Mechanistic studies:

  • Investigate ARGLU1's role in enhancing transcription of mismatch repair genes (MLH3, MSH2, MSH3, MSH6)

  • Use ChIP with ARGLU1 antibodies to study recruitment to promoters of these genes

  • Co-IP to detect interaction with transcription factors SP1 and YY1

• Therapeutic potential assessment:

  • Use ARGLU1 antibodies to monitor protein induction after treatment with saRNA (small activating RNA)

  • Test efficacy in patient-derived xenograft (PDX) models

  • Validate specificity of therapeutic approach through antibody-based detection

What are the key considerations when selecting between polyclonal and monoclonal antibodies for ARGLU1 detection?

Most commercially available ARGLU1 antibodies are rabbit polyclonal antibodies (e.g., HPA034962, HPA056792) , which recognize epitopes from various regions of the protein, including the C-terminal domain: "KREELERILEENNRKIAEAQAKLAEEQLRIVEEQRKIHEERMKLEQERQRQQKEEQKIILGKGKSR" .

What is the recommended protocol for generating custom ARGLU1 antibodies for specialized research applications?

Based on successful antibody generation approaches:

• Antigen selection:

  • For full protein antibodies: Use full-length human ARGLU1 (AAH50434, 1 a.a. ~ 273 a.a.)

  • For domain-specific antibodies: Target either the N-terminal arginine-rich region or C-terminal glutamate-rich region

  • For peptide antibodies: Use validated sequences such as "Cys-KEEQKIILGKGKSRPKLSFSLKTQD" or "KREELERILEENNRKIAEAQAKLAEEQLRIVEEQRKIHEERMKLEQERQRQQKEEQKIILGKGKSR"

• Immunization protocol:

  • Conjugate peptides to carrier proteins (KLH or BSA) if using peptide antigens

  • Use multiple host animals (typically rabbits) for polyclonal antibody generation

  • Follow standard immunization schedules with complete and incomplete adjuvants

• Purification:

  • Affinity purify using peptide columns before use

  • Validate through Western blotting against recombinant protein and endogenous ARGLU1

• Validation:

  • Test on protein arrays with 364 human recombinant protein fragments

  • Validate on IHC tissue arrays of 44 normal human tissues and 20 cancer tissues

  • Confirm specificity by immunoblotting or immunostaining in ARGLU1 knockdown cells

The most effective antibodies reported have been generated in rabbits using specific peptide sequences from the ARGLU1 protein .